These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20181970)

  • 1. Lasofoxifene in postmenopausal women with osteoporosis.
    Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
    N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Another selective estrogen-receptor modulator for osteoporosis.
    Becker C
    N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
    [No Abstract]   [Full Text] [Related]  

  • 3. Lasofoxifene for postmenopausal women with osteoporosis.
    Silva-Fernández L; Andreu JL
    N Engl J Med; 2010 Jun; 362(23):2228; author reply 2228-9. PubMed ID: 20568310
    [No Abstract]   [Full Text] [Related]  

  • 4. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
    Ensrud K; LaCroix A; Thompson JR; Thompson DD; Eastell R; Reid DM; Vukicevic S; Cauley J; Barrett-Connor E; Armstrong R; Welty F; Cummings S
    Circulation; 2010 Oct; 122(17):1716-24. PubMed ID: 20937977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
    LaCroix AZ; Powles T; Osborne CK; Wolter K; Thompson JR; Thompson DD; Allred DC; Armstrong R; Cummings SR; Eastell R; Ensrud KE; Goss P; Lee A; Neven P; Reid DM; Curto M; Vukicevic S;
    J Natl Cancer Inst; 2010 Nov; 102(22):1706-15. PubMed ID: 21051656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tipping the balance for the primary prevention of breast cancer.
    Vogel VG
    J Natl Cancer Inst; 2010 Nov; 102(22):1683-5. PubMed ID: 21051657
    [No Abstract]   [Full Text] [Related]  

  • 8. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
    Archer DF
    Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
    [No Abstract]   [Full Text] [Related]  

  • 9. Lasofoxifene for postmenopausal women with osteoporosis.
    Katzeff BS
    N Engl J Med; 2010 Jun; 362(23):2227-8; author reply 2228-9. PubMed ID: 20568309
    [No Abstract]   [Full Text] [Related]  

  • 10. Lasofoxifene in osteoporosis and its place in therapy.
    Swan VJ; Hamilton CJ; Jamal SA
    Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lasofoxifene for postmenopausal women with osteoporosis.
    Malozowski S
    N Engl J Med; 2010 Jun; 362(23):2227; author reply 2228-9. PubMed ID: 20558377
    [No Abstract]   [Full Text] [Related]  

  • 12. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
    Hadji P
    Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract]   [Full Text] [Related]  

  • 14. Third-generation SERMs may face uphill battle.
    Schmidt C
    J Natl Cancer Inst; 2010 Nov; 102(22):1690-2. PubMed ID: 21060064
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Peterson GM; Naunton M; Tichelaar LK; Gennari L
    Ann Pharmacother; 2011 Apr; 45(4):499-509. PubMed ID: 21467260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis.
    Komm BS; Chines AA
    Maturitas; 2012 Mar; 71(3):221-6. PubMed ID: 22196312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Gennari L
    Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.